

Financial Tear Sheet


Corporate Profile

Amgen, the world's largest biotechnology company, uses science and innovation in an effort to dramatically improve people's lives. Amgen aspires to be the world's best human therapeutics company.

Our researchers harness the powerful tools of cellular and molecular biology and medicinal chemistry to discover, develop and commercialize naturally occurring proteins, antibodies and small molecules, with the goal of extending the reach of science to unleash the body's own powerful therapeutic responses. Amgen's research and product development programs aim to help patients in four critical areas: nephrology, hematology and oncology, bone and inflammation, neurology and endocrinology.

Stock Performance

AMGN (COMMON STOCK)	
Exchange	NASDAQ (US Dollar)
Price	\$182.03
Change (%)	▼ 0.52 (0.28%)
Volume	2,548,994
52 Week Low	\$152.16
Market Cap	\$131,163,945,639
Rolling EPS	2.69
PE Ratio	67.6691
Shares Outstanding	720,562,246



Data as of 03/20/18 4:15 p.m. ET

Recent Headlines

03/09/18

New Analyses Show Payer Utilization Management Criteria Deny Access To PCSK9 Inhibitors For Patients At The Highest Risk For Subsequent Cardiovascular Events

03/08/18

Amgen Announces Final Results Of Tender Offer

03/07/18


Amgen Announces 2018 Second Quarter Dividend

Upcoming Events

There are currently no events scheduled.

Analyst Estimates / Ratings

Mean Recommendation: **2.4**



Unable to fulfill request.

SEC Filings

FILING DATE	FORM
03/19/18	4
03/09/18	4
03/09/18	4
03/09/18	4

Financial Reports

Q4 2017 Financial Results

Presentations

02/01/18 Q4 2017 Amgen Earnings
Conference Call Presentation

Data provided by Nasdaq. Minimum 15 minutes delayed.